<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230607058402N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-23</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effectiveness of the Intraperitoneal Irrigation with tumescent solution on the intensity of postoperative pain in laparoscopic cholecystectomy patients</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effectiveness of the Intraperitoneal Irrigation with tumescent solution on the intensity of postoperative pain in laparoscopic cholecystectomy patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70591</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is a double-blind randomized clinical trial that is conducted in patients with symptomatic gallstones who refer to educational-therapeutic centers in the province and are candidates for laparoscopic cholecystectomy according to the order of the surgeon. Using the method of random blocks (Balance block randomization), they are assigned to two treatment groups A and B, the balanced randomization method for the participants in the randomized controlled clinical trial study of intraperitoneal lavage with Tamosent solution (group A) and intraperitoneal lavage with normal saline alone (group B) on postoperative pain intensity in laparoscopic cholecystectomy patients, Blinding description: Checklist information is provided by the secretary of the department in which people with national code are registered to the person responsible for the analysis and statistical analysis of the plan. After entering SPSS and coding 1 and 2, the results of the evaluation will be analyzed by the statistics professor, separated into intervention and control groups (which only the secretary of the department knows about). It is not known which washing method it received. The analyst and the data safety monitoring committee are not aware of which solution the patients received.</study_design>
      <phase>3</phase>
      <hc_freetext>Laparoscopic cholecystectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intraperitoneal washing with Tamosent solution (group A): At the beginning of surgery and right after inflating the pneumoperitoneum and before any dissection of the gallbladder, the surgeon injects 200 ml of Tamosent solution (a mixture of 5 ampoules of 0.5% bupivacaine and one vial of 7.5% sodium bicarbonate in 450 ml of normal Saline) will be injected in the space under the diaphragm and the gallbladder area with the guidance of the camera. The patient was kept in the Trendelenburg position for 5 to 10 minutes. After that, the patients will be placed in the anti-Trendelenburg position to start the surgery, and the laparoscopic operation will be performed in a standard way, and the rest of the serum containing the Tamosent solution will be injected during the surgery and at the end of the operation. Intervention 2: Control group: Intraperitoneal lavage with normal saline alone (group B): After placing the laparoscopic ports, the patients will be placed in the anti-Trendelenburg position to start the surgery, and the laparoscopic operation will be performed in a standard way, and at the end of the operation, 500 ml of 0.9% normal saline will be used to wash the upper surface of the liver and below the surgical bed. A semi-right aperture will be used. After the removal of the gallbladder is completed in both groups, fluids will be completely aspirated before the pneumoperitoneum is drained. At the end of the surgery, CO2 is carefully drained by manually compressing the abdomen with open trocars (especially through the epigastric trocar) and the drain will not be used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Satisfaction of participants</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amirarad mahmoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar street</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>34197-58911</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>amiraradmahmoudi@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amirarad Mahmoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University campus building, Bahonar Blvd</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>34197-58911</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>amiraradmahmoudi@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients diagnosed with symptomatic gallstones or chronic cholecystitis</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant women
aged &lt;25 years and &gt;70 years
emergency cholecystectomy
jaundice
intraoperative injury to the intestine or bile duct
intraoperative bleeding
gangrenous cholecystitis or emphysema
obstructive jaundice
choledocholithiasis
coagulopathy
gallbladder rupture during surgery or damage to the common bile duct
cholangitis
pancreatitis
gallbladder carcinoma and its abnormalities
previous upper abdominal surgery
Unwillingness to participate in the study
patients with a history of drug or alcohol abuse</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K80.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Calculus of gallbladder with acute cholecystitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intraperitoneal washing with Tamosent solution (group A): At the beginning of surgery and right after inflating the pneumoperitoneum and before any dissection of the gallbladder, the surgeon injects 200 ml of Tamosent solution (a mixture of 5 ampoules of 0.5% bupivacaine and one vial of 7.5% sodium bicarbonate in 450 ml of normal Saline) will be injected in the space under the diaphragm and the gallbladder area with the guidance of the camera. The patient was kept in the Trendelenburg position for 5 to 10 minutes. After that, the patients will be placed in the anti-Trendelenburg position to start the surgery, and the laparoscopic operation will be performed in a standard way, and the rest of the serum containing the Tamosent solution will be injected during the surgery and at the end of the operation.</i_keyword>
      <i_keyword>Control group: Intraperitoneal lavage with normal saline alone (group B): After placing the laparoscopic ports, the patients will be placed in the anti-Trendelenburg position to start the surgery, and the laparoscopic operation will be performed in a standard way, and at the end of the operation, 500 ml of 0.9% normal saline will be used to wash the upper surface of the liver and below the surgical bed. A semi-right aperture will be used. After the removal of the gallbladder is completed in both groups, fluids will be completely aspirated before the pneumoperitoneum is drained. At the end of the surgery, CO2 is carefully drained by manually compressing the abdomen with open trocars (especially through the epigastric trocar) and the drain will not be used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity of postoperative pain. Timepoint: Assessment of shoulder and abdominal pain intensity at 6, 12 and 24 hours during 24 hours after surgery. Method of measurement: Visual Analog Score (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-19</approval_date>
        <contact_name>Ethics committee of qazvin University of Medical Sciences</contact_name>
        <contact_address>Research and Technology deputy ,Mavaddat Alley,Shahid Beheshti Blvd,Qazvin Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
